Skip to main content
PLRX
NASDAQ Life Sciences

Pliant Q3 Loss Narrows to $24.4M; Discloses Nasdaq $1.00 Bid-Price Deficiency

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.78
Mkt Cap
$45.822M
52W Low
$0.733
52W High
$1.815
52W Position info
6.5% above low
Off High info
57% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

PLRX is trading near its 52-week low of $0.733 (6.5% above the low).

Summary

Pliant's Q3 net loss narrowed to $24.4M from $26.3M, but cash dropped to $142.6M and the filing newly discloses the stock has traded below Nasdaq's $1.00 minimum bid since October 9, 2026.


Key Events · Earnings and Guidance · PLRX

  • Q3 Loss Narrows on Cost Cuts

    Net loss was $24.4M versus $26.3M a year earlier; R&D was flat at $17.9M and G&A fell $2.5M to $7.8M after the 2025 restructuring.

  • Cash Falls to $142.6M

    Cash, cash equivalents, short-term investments and restricted cash dropped from $192.4M at December 31, 2025 to $142.6M at September 30, 2026; nine-month operating cash burn was $49.0M versus $110.5M a year earlier.

  • Nasdaq Bid-Price Deficiency Disclosed

    The stock closed at $0.80 on November 9, 2026 and has not closed above $1.00 since October 9, 2026, putting the company below Nasdaq's minimum bid price requirement.

  • FORTIFY Enrollment Ahead of Schedule

    The Phase 1b trial of PLN-101095 plus pembrolizumab is enrolling ahead of plan across NSCLC, ccRCC and high-TMB cohorts, with interim data expected in 2027.


Analysis · PLRX · Life Sciences

The quarter itself is unremarkable — R&D held flat at $17.9M and G&A fell $2.5M to $7.8M on lower headcount, so the net loss narrowed to $24.4M from $26.3M. What matters is the balance sheet and the listing risk. Cash, equivalents, short-term investments and restricted cash fell to $142.6M from $192.4M at year-end 2025, and management still says that funds operations for the next 12 months and beyond, but the company now also discloses that its stock closed at $0.80 on November 9, 2026 and has not closed above $1.00 since October 9, 2026 — a Nasdaq minimum bid price problem that did not appear in the prior quarter's baseline. With a $50.0M at-the-market program in place and unused, any equity raise at sub-$1 prices would be heavily dilutive, and a reverse split becomes a live possibility to cure the deficiency.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PLRX was trading at $0.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $45.8M. The 52-week trading range was $0.73 to $1.82. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PLRX - Latest Insights

PLRX
Aug 11, 2026, 4:19 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.07
Real-time Price: $0.697 info
Change: -$0.373 (-35%) info
Market Cap: $43.16M info
PLRX
Aug 11, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.07
Real-time Price: $0.697 info
Change: -$0.373 (-35%) info
Market Cap: $43.16M info
PLRX
Aug 11, 2026, 4:08 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.05
Real-time Price: $0.697 info
Change: -$0.353 (-34%) info
Market Cap: $43.16M info
PLRX
May 11, 2026, 4:10 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.23
Real-time Price: $0.697 info
Change: -$0.5291 (-43%) info
Market Cap: $43.16M info
PLRX
May 11, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.23
Real-time Price: $0.697 info
Change: -$0.533 (-43%) info
Market Cap: $43.16M info